Innate Pharma

Innate Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Company Details

Employees
198
Founded
-
Address
117, Avenue De Luminy, Marseille,provence-Alpes-Côte D’azur 13009,france
Phone
+33 (0)4 30 30 30 30
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Marseille, Provence-Alpes-Côte d’Azur
Looking for a particular Innate Pharma employee's phone or email?

Innate Pharma Questions

News

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 - Yahoo Finance

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 Yahoo Finance

Innate Pharma Reports First Half 2025 Business Update and Financial Results - Business Wire

Innate Pharma Reports First Half 2025 Business Update and Financial Results Business Wire

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event - Yahoo Finance

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event Yahoo Finance

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025 - Yahoo Finance

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025 Yahoo Finance

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results - Business Wire

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results Business Wire

Innate Pharma H1 Net Loss Shrinks, Plans 30% Workforce Cut, Stock Drops - Nasdaq

Innate Pharma H1 Net Loss Shrinks, Plans 30% Workforce Cut, Stock Drops Nasdaq

Sanofi expands NK cell engager deal with Innate - FirstWord Pharma

Sanofi expands NK cell engager deal with Innate FirstWord Pharma

Innate Pharma doses first patient in Nectin-4 ADC trial - Clinical Trials Arena

Innate Pharma doses first patient in Nectin-4 ADC trial Clinical Trials Arena

Innate Pharma Announces €15M Investment by Sanofi - Business Wire

Innate Pharma Announces €15M Investment by Sanofi Business Wire

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress - Yahoo Finance

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress Yahoo Finance

Sanofi enters cancer drug-development deals with Warp Drive, Innate Pharma - FirstWord Pharma

Sanofi enters cancer drug-development deals with Warp Drive, Innate Pharma FirstWord Pharma

Innate Pharma Q1 Revenue Declines, Stock Down - Nasdaq

Innate Pharma Q1 Revenue Declines, Stock Down Nasdaq

and Announces Sanofi’s Intention to Make a Strategic Investment in the Company - Business Wire

and Announces Sanofi’s Intention to Make a Strategic Investment in the Company Business Wire

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome - Business Wire

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome Business Wire

How the Narrative Around Innate Pharma Is Shifting After Recent Strategic Decisions - Yahoo Finance

How the Narrative Around Innate Pharma Is Shifting After Recent Strategic Decisions Yahoo Finance

Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance

Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ... Yahoo Finance

Sanofi Deepens NK Cell Therapy Partnership with Innate Pharma - BioSpace

Sanofi Deepens NK Cell Therapy Partnership with Innate Pharma BioSpace

French Biotech Strikes Deal with Novo Nordisk for New Cancer Drug - Labiotech.eu

French Biotech Strikes Deal with Novo Nordisk for New Cancer Drug Labiotech.eu

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 - GlobeNewswire

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 GlobeNewswire

Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial - Business Wire

Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial Business Wire

INNATE PHARMA RECEIVES PRIME DESIGNATION FROM THE EUROPEAN - GlobeNewswire

INNATE PHARMA RECEIVES PRIME DESIGNATION FROM THE EUROPEAN GlobeNewswire

23andMe, Innate Pharma Tap Antibodies to Target NK Cells for Cancer - BioSpace

23andMe, Innate Pharma Tap Antibodies to Target NK Cells for Cancer BioSpace

AZ cancer head Mahjoubi departs to helm Innate Pharma - Fierce Pharma

AZ cancer head Mahjoubi departs to helm Innate Pharma Fierce Pharma

Innate Pharma’s ANKET NK Engager Platform Eradicates Tumors Safely and Efficiently - BioSpace

Innate Pharma’s ANKET NK Engager Platform Eradicates Tumors Safely and Efficiently BioSpace

AstraZeneca pulls leukemia drug Lumoxiti off market after disappointing sales - Fierce Pharma

AstraZeneca pulls leukemia drug Lumoxiti off market after disappointing sales Fierce Pharma

Kiadis to be shuttered, Amunix sold off amid Sanofi pipeline shift - FirstWord Pharma

Kiadis to be shuttered, Amunix sold off amid Sanofi pipeline shift FirstWord Pharma

AstraZeneca moves to pull leukaemia drug Lumoxiti in the US - FirstWord Pharma

AstraZeneca moves to pull leukaemia drug Lumoxiti in the US FirstWord Pharma

Innate Pharma (IPHA) Stock Price, News & Analysis - MarketBeat

Innate Pharma (IPHA) Stock Price, News & Analysis MarketBeat

Innate Pharma and Novo Nordisk pen early I-O cancer drug deal - Fierce Biotech

Innate Pharma and Novo Nordisk pen early I-O cancer drug deal Fierce Biotech

Fierce JPM Week: AstraZeneca cancer R&D head marks Imfinzi as 'core backbone' of oncology strategy with the right combo—including treme - Fierce Pharma

Fierce JPM Week: AstraZeneca cancer R&D head marks Imfinzi as 'core backbone' of oncology strategy with the right combo—including treme Fierce Pharma

AstraZeneca’s Imfinzi regimen misses the mark in setback for ambitious lung cancer 2030 goal - Fierce Pharma

AstraZeneca’s Imfinzi regimen misses the mark in setback for ambitious lung cancer 2030 goal Fierce Pharma

Novartis doubles down on IFM's innate immune drugs, acquiring subsidiary - FirstWord Pharma

Novartis doubles down on IFM's innate immune drugs, acquiring subsidiary FirstWord Pharma

As Bristol Myers reveals trial failure, AstraZeneca's Imfinzi stays king in stage 3 lung cancer - Fierce Pharma

As Bristol Myers reveals trial failure, AstraZeneca's Imfinzi stays king in stage 3 lung cancer Fierce Pharma

AstraZeneca plows $520M into manufacturing and R&D in France as it slims down elsewhere - Fierce Pharma

AstraZeneca plows $520M into manufacturing and R&D in France as it slims down elsewhere Fierce Pharma

Sanofi to utilise Scribe's CRISPR platform to develop cancer cell therapies - FirstWord Pharma

Sanofi to utilise Scribe's CRISPR platform to develop cancer cell therapies FirstWord Pharma

Disgruntled AstraZeneca sues former executive Luke Miels for jumping to GlaxoSmithKline post - Fierce Pharma

Disgruntled AstraZeneca sues former executive Luke Miels for jumping to GlaxoSmithKline post Fierce Pharma

Publication of Explore Covid-19 translationnal study findings - Inserm Newsroom - Inserm

Publication of Explore Covid-19 translationnal study findings - Inserm Newsroom Inserm

Top Innate Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant